What's Hot

View all perspectives
      RT @Yuz6Yusof: #EULAR2023 #POS0116 How does Voclosporin fare in #lupus pts with heavy proteinuria (=>2g/day)? Pooled

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 4 months ago
      #EULAR2023 #POS0116 How does Voclosporin fare in #lupus pts with heavy proteinuria (=>2g/day)? Pooled Analyses from Phase 2&3 RCTs showed consistent improvement in renal response regardless of demographics or clinical characteristics. An option this resistant group @RheumNow https://t.co/AmZ0fStJrW
      RT @AurelieRheumo: TNFi & Disease activity-guided dose optimization in RA⬇️prog of ADA or ETA daily dose (100%66

      Aurelie Najm AurelieRheumo

      1 year 4 months ago
      TNFi & Disease activity-guided dose optimization in RA⬇️prog of ADA or ETA daily dose (100%66%50%0%) 10yrs followup in 170pts ⭐️74% tapered until full discontinuation ⭐️Median time to restart 8 mo ⭐️21% never restarted! What's lacking? % of recovery @Rheumnow OP0131 #EULAR23 https://t.co/Ms6lqQ7cWf
      RT @drdavidliew: Rituximab in RA - do you need to maintain B cell depletion?

      Well, in this Paris cohort, if you divide

      David Liew drdavidliew

      1 year 4 months ago
      Rituximab in RA - do you need to maintain B cell depletion? Well, in this Paris cohort, if you divide up patients by B cell depletion (at time of next infusion) - no diff in efficacy. Bias possible but B cell depletion in RA isn’t the hill to die on POS0636 #EULAR2023 @RheumNow https://t.co/GLdu9YkL7g
      RT @AurelieRheumo: CareRA trial:
      3 months addition of LEF vs. ETA in pts resistant to COBRA-Slim regimen (MTX 15 mg/w

      Aurelie Najm AurelieRheumo

      1 year 4 months ago
      CareRA trial: 3 months addition of LEF vs. ETA in pts resistant to COBRA-Slim regimen (MTX 15 mg/w + step-down prednisone): After 2 years, no difference in dis control but those who received ETA early were treated more frequently w/ csDMARD monotherapy #EULAR23 @RheumNow OP0129 https://t.co/YwSoZWi375
      RT @Janetbirdope: Don’t be ‘rash’, get adult immune compromised Pts vaccinated against #shingles #varicella #zoste

      Janet Pope Janetbirdope

      1 year 4 months ago
      Don’t be ‘rash’, get adult immune compromised Pts vaccinated against #shingles #varicella #zoster K Winthrop has research re #HZ #vaccination with #Shingrix in #Upadacitinib at #EULAR2023 #OP0225 Bottom line-get #immunecompromised Pts with #rheumatoidarthritis jabbed! @RheumNow
      RT @Yuz6Yusof: #EULAR2023 #POS0115 Can we minimise placebo response in #lupus trials? Post-hoc analysis of Phase 2 RCT D

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 4 months ago
      #EULAR2023 #POS0115 Can we minimise placebo response in #lupus trials? Post-hoc analysis of Phase 2 RCT Dapirolizumab (CD40-CD40L-i) showed greater response in acute flare with Normal Complement levels in the PBO group. Could Low Complement be used for trial entry? @RheumNow https://t.co/8aRq5tWi97
      RT @drdavidliew: “You don’t need MTX with TCZ for RA”

      Err, well:
      - just like TNFi, you def can get ADAb to TCZ
      -

      David Liew drdavidliew

      1 year 4 months ago
      “You don’t need MTX with TCZ for RA” Err, well: - just like TNFi, you def can get ADAb to TCZ - they definitely lead to lower response rates - MTX co-admin reduces ADAb Seems like a good idea to me, but your call 🤷‍♂️ Bitoun, Mariette et al POS0630 #EULAR2023 @RheumNow https://t.co/2jOAqA6YZ3
      RT @synovialjoints: The risk of demyelination with TNFi is low but real. Slight increase of risk was found in male RA pa

      Dr. Antoni Chan synovialjoints

      1 year 4 months ago
      The risk of demyelination with TNFi is low but real. Slight increase of risk was found in male RA patients. The small number of events is reassuring. Careful consideration is recommended in individuals at highest risk of demyelinating diseases Abst#OP0135 #EULAR2023 @RheumNow https://t.co/YT6ZrJTjU0
      RT @synovialjoints: In polyrefractory RA patients, half did not have any PDUS change on ultrasound and/or had normal CRP

      Dr. Antoni Chan synovialjoints

      1 year 4 months ago
      In polyrefractory RA patients, half did not have any PDUS change on ultrasound and/or had normal CRP levels, showing that in the other half, new mechanisms of action for treatment is required by David P, Abst#OP0134 ##EULAR2023 @RheumNow https://t.co/TaY7uGU0bg
      RT @Yuz6Yusof: #EULAR2023 #OP0142 From #Lupus to #Sjogren. A phase 2 RCT in China showed more patients on Telitacicept (

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 4 months ago
      #EULAR2023 #OP0142 From #Lupus to #Sjogren. A phase 2 RCT in China showed more patients on Telitacicept (BAFF/APRIL-i) achieved significant reduction in ESSDAI at Wk24 vs PBO. Trend to improvement in glandular function. Intriguing option & will await Phase 3 global RCT @RheumNow https://t.co/BCiohuAfP3
      RT @synovialjoints: No relationship between MTX-PG levels in terms of efficacy by SDAI remission but higher MTX-PG level

      Dr. Antoni Chan synovialjoints

      1 year 4 months ago
      No relationship between MTX-PG levels in terms of efficacy by SDAI remission but higher MTX-PG levels related to adverse events by Tamai H, Abstr #OP0128 #EULAR2023 @RheumNow https://t.co/TiO5eeYlnS
      RT @synovialjoints: JAKi have superior effectiveness at 6 months compared to TNFi and the efficacy was similar in those

      Dr. Antoni Chan synovialjoints

      1 year 4 months ago
      JAKi have superior effectiveness at 6 months compared to TNFi and the efficacy was similar in those with and and without safety risk (increased age, CV risk, smoker) by Hannah Bower, Abst#0133 #EULAR2023 @RheumNow https://t.co/Pt6EoN6323
      RT @Yuz6Yusof: #EULAR2023 #OP0143 Promising therapy. A Phase 2 RCT of Dazodalidep (CD40L-i) in #Sjogren showed significa

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 4 months ago
      #EULAR2023 #OP0143 Promising therapy. A Phase 2 RCT of Dazodalidep (CD40L-i) in #Sjogren showed significantly more patients on DAZ group met reduction in ESSDAI vs placebo. Interesting to see higher hurdle ESSDAI favoured DAZ Group. Phase 3 RCTs are underway @RheumNow https://t.co/I9uHxvRlnr
      RT @drdavidliew: We’re getting better at understanding different types of refractory RA (D2T RA)

      We see differences w

      David Liew drdavidliew

      1 year 4 months ago
      We’re getting better at understanding different types of refractory RA (D2T RA) We see differences with refractory RA subtypes: PIRRA (persistently inflamm on USS), and NIRRA (non-inflamm) hopefully moving to data-driven Rx approaches for D2T RA? OP0134 #EULAR2023 @RheumNow https://t.co/vX5IK5O9Wm
      RT @Janetbirdope: Difficult to treat #rheumatoid #arthritis is a grab bag of multi drug failures or intolerant with high

      Janet Pope Janetbirdope

      1 year 4 months ago
      Difficult to treat #rheumatoid #arthritis is a grab bag of multi drug failures or intolerant with high or LOW disease activity 3 groups and diff reasons for failure and diff risk factors. ? Sunset the D2T Pts? OP0117 #EULAR2023 @RheumNow @eular_org https://t.co/1qPMq32kVz

      Podcasts

      • ANA+ Consult (10.18.2024)
      • Dot The I, Cross The T (10.11.2024)
      • Stop Counting Bugs (10.4.2024)

      Catch up on Conference Podcasts

      Key Conference Topics

      Additional Topics

      Filter by Type

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright {{ 'now'|date('Y') }} All Rights Reserved.